Press release
Thyroid Cancer Market Projected to Reach USD 7.6 Billion by 2034
Thyroid Cancer
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71583
The treatment landscape has evolved significantly in the past decade, with targeted therapies (tyrosine kinase inhibitors), immunotherapies, and advanced diagnostics improving survival outcomes. With rising prevalence, supportive regulatory frameworks, and growing pharmaceutical R&D, the global Thyroid Cancer Market is expected to expand steadily through 2034.
Market Overview
• Market Size 2024: USD 3.9 billion
• Forecast 2034: USD 7.6 billion
• CAGR (2024-2034): 7.0%
This growth is supported by increasing incidence, earlier detection through screening programs, and adoption of novel therapeutics.
Key Growth Drivers
• Rising incidence of thyroid cancer globally, especially papillary carcinoma.
• Expansion of tyrosine kinase inhibitors (TKIs) and targeted therapies.
• Advances in molecular diagnostics and biomarker testing.
• Supportive FDA and EMA approvals, including orphan drug designations.
• Growing healthcare expenditure and patient access in emerging markets.
Key Challenges
• High cost and side effects of targeted therapies.
• Limited treatment options for anaplastic thyroid carcinoma (ATC).
• Resistance to radioactive iodine in refractory cases.
• Unequal access to advanced therapies in developing regions.
Leading Players
Prominent companies include Eisai Co., Ltd. (Lenvatinib), Bayer AG (Sorafenib), Novartis AG, Roche Holding AG, Eli Lilly and Company, Bristol Myers Squibb, Pfizer Inc., Sanofi, Merck & Co., and Amgen Inc.
Segmentation Analysis
The Thyroid Cancer Market can be segmented as follows:
• By Type
o Papillary Thyroid Cancer
o Follicular Thyroid Cancer
o Medullary Thyroid Cancer (MTC)
o Anaplastic Thyroid Cancer (ATC)
• By Therapy Type
o Surgery (Thyroidectomy, Lobectomy)
o Radioactive Iodine Therapy
o Hormone Therapy
o Chemotherapy (limited use)
o Targeted Therapy (TKIs, RET inhibitors, BRAF/MEK inhibitors)
o Immunotherapy (Checkpoint Inhibitors, Emerging CAR-T)
• By Diagnostic Method
o Imaging (Ultrasound, CT, MRI, PET)
o Fine Needle Aspiration Biopsy (FNAB)
o Genetic & Molecular Testing
• By End Use
o Hospitals & Oncology Centers
o Specialty Clinics
o Research & Academic Institutes
Segmentation Summary: Papillary thyroid cancer remains the most common type, but the fastest growth is in targeted therapies for advanced MTC and ATC, reflecting unmet clinical needs and regulatory support for innovative treatments.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71583/thyroid-cancer-market
Regional Analysis
• North America
Largest market due to high prevalence, early adoption of targeted therapies, and strong FDA approval pipeline. The U.S. dominates with advanced diagnostic infrastructure.
• Europe
Significant growth supported by EMA approvals and established healthcare systems. Germany, France, and the UK lead the regional market.
• Asia-Pacific (APAC)
Expected to record the fastest CAGR through 2034, driven by rising incidence in China, India, and Japan, coupled with expanding oncology care infrastructure.
• Middle East & Africa
Moderate growth, with improved oncology access in GCC countries, but limited availability of novel therapies in broader regions.
• Latin America
Brazil and Mexico dominate, with growing adoption of TKIs, though affordability and reimbursement barriers persist.
Regional Summary: North America and Europe dominate the current market, while Asia-Pacific is the fastest-growing region, reflecting rising disease burden and improved healthcare investment.
Market Dynamics
Growth Drivers
• Integration of NGS and biomarker-driven precision medicine in thyroid cancer care.
• Expansion of RET inhibitors (selpercatinib, pralsetinib) for medullary and RET-fusion thyroid cancers.
• Rising awareness campaigns and screening initiatives.
• Increasing collaborations between pharma and research institutes.
Challenges
• Resistance to TKIs and radioactive iodine therapies.
• High treatment costs and uneven reimbursement.
• Limited pipeline drugs for aggressive ATC.
• Diagnostic variability in low-resource settings.
Emerging Trends
• Development of BRAF/MEK inhibitors for refractory cases.
• Expansion of immune checkpoint inhibitors in thyroid cancer.
• Growth of liquid biopsy applications for early detection and monitoring.
• Integration of AI-powered diagnostic imaging to improve accuracy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71583
Competitor Analysis
Major Players
• Eisai Co., Ltd. (Lenvatinib)
• Bayer AG (Sorafenib)
• Novartis AG
• Roche Holding AG
• Eli Lilly and Company
• Bristol Myers Squibb
• Pfizer Inc.
• Sanofi
• Merck & Co.
• Amgen Inc.
Competitive Landscape
The market is moderately consolidated, with Eisai and Bayer leading with their TKIs (Lenvatinib, Sorafenib). Novartis, Roche, and BMS are advancing immunotherapy and biomarker-driven solutions, while emerging biotech firms focus on RET inhibitors and rare cancer drug development. Strategic collaborations, licensing agreements, and orphan drug designations remain key competitive strategies.
Conclusion
The Thyroid Cancer Market is projected to grow from USD 3.9 billion in 2024 to USD 7.6 billion by 2034, at a CAGR of 7.0%. Rising prevalence, strong pipelines of targeted and immunotherapies, and advances in diagnostics will drive this growth.
Key Takeaways:
• Market to double by 2034, at 7.0% CAGR.
• Papillary thyroid cancer dominates incidence, but targeted therapy for MTC and ATC is the fastest-growing area.
• North America and Europe lead, while APAC is the fastest-growing region.
• Competitive dynamics shaped by TKI leaders, biotech innovators, and immunotherapy expansion.
The next decade will mark a transformative phase for thyroid cancer treatment, as precision medicine, immuno-oncology, and AI-driven diagnostics offer improved survival and quality of life for patients worldwide.
This report is also available in the following languages : Japanese (甲状腺がん市場), Korean (갑상선암 시장), Chinese (甲状腺癌市场), French (Marché du cancer de la thyroïde), German (Markt für Schilddrüsenkrebs), and Italian (Mercato del cancro alla tiroide), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/reports/71583/thyroid-cancer-market#request-a-sample
Our More Reports:
Goitre Market
https://exactitudeconsultancy.com/reports/72019/goitre-market
Gouty Arthritis (Gout) Market
https://exactitudeconsultancy.com/reports/72020/gouty-arthritis-gout-market
Hereditary Hemochromatosis (HH) Market
https://exactitudeconsultancy.com/reports/72021/hereditary-hemochromatosis-hh-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Market Projected to Reach USD 7.6 Billion by 2034 here
News-ID: 4171879 • Views: …
More Releases from Exactitude Consultancy
Cholangiocarcinoma (CCA) Market Growth, Trends, Consumer Demand and Key Opportun …
Introduction
Cholangiocarcinoma (CCA), or bile duct cancer, is a rare but aggressive malignancy that arises from the epithelial cells of the bile ducts. It is categorized into intrahepatic, perihilar, and distal cholangiocarcinoma, with each subtype posing unique diagnostic and therapeutic challenges. CCA accounts for approximately 3% of all gastrointestinal cancers, but its incidence is rising worldwide due to increasing risk factors such as chronic liver disease, hepatitis infections, and parasitic infestations…
Triple Negative Breast Neoplasms Market is expected to reach USD 8.0 billion by …
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. Representing about 10-15% of all breast cancers, TNBC disproportionately affects younger women and certain ethnic groups. Due to its heterogeneity, high recurrence rates, and limited treatment options, TNBC is associated with poor prognosis compared to other breast cancer types.
Download Full PDF Sample Copy of Market Report…
Castrate-Sensitive Prostate Cancer Market Set to Witness Significant Growth by 2 …
Introduction
Prostate cancer remains one of the most commonly diagnosed cancers in men worldwide. Within this space, castrate-sensitive prostate cancer (CSPC) refers to prostate cancer that still responds to therapies lowering testosterone levels, typically through androgen deprivation therapy (ADT). While ADT has long been the mainstay of CSPC treatment, disease progression remains a challenge, often leading to castrate-resistant prostate cancer (CRPC).
In recent years, the treatment paradigm for CSPC has changed dramatically.…
Acute Myeloid Leukemia (AML) Market 2025-2034 Business Outlook, Critical Insight …
Introduction
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation of abnormal myeloid cells in the bone marrow and blood. AML is one of the most common types of acute leukemia in adults, with incidence rising in older populations. Despite improvements in standard-of-care regimens, AML remains a disease with poor long-term survival, especially in relapsed and refractory cases.
Over the past decade, the treatment landscape for AML…
More Releases for Thyroid
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Thyroid Function Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for thyroid function tests has witnessed substantial growth in the past few years. The market is projected to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with an…
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
The Thyroid Function Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Thyroid Function Test Market Size During the Forecast Period?
The thyroid function test market has grown significantly in recent years. It is expected to grow from $1.7 billion in 2024…
Thyroid Function Test Market Report 2024 - Thyroid Function Test Market Growth A …
"The Business Research Company recently released a comprehensive report on the Global Thyroid Function Test Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Thyroid Ablation Devices Market
Alarming rise in prevalence of thyroid cancer, advancements in thyroid ablation system, rise in government & private funds for development of healthcare sectors, and increase in number of thyroid nodule cases are expected to notably contribute toward the growth of the global thyroid ablation devices market during the forecast period.
Rise in prevalence of thyroid cancer and thyroid nodules, demand for minimally invasive procedures, and technological advancements in ablation devices drive…
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of…
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view…
